- Fadraciclib
-
- $37.00
-
2026-07-27
- CAS:1070790-89-4
- Purity: 99.75%
- Supply Ability: 10g
|
| | CYC-065 Basic information |
| Product Name: | CYC-065 | | Synonyms: | CYC065; CYC-065; CYC 065;1070790-89-4;CDK259;CYC065 base;CPD1574;CYC065, CDK259;CYC065 free base;2-Pentanol, 3-[[6-[[(4,6-dimethyl-3-pyridinyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-, (2R,3S)-;Fadraciclib（CYC065） | | CAS: | 1070790-89-4 | | MF: | C21H31N7O | | MW: | 397.52 | | EINECS: | | | Product Categories: | api | | Mol File: | 1070790-89-4.mol |  |
| | CYC-065 Chemical Properties |
| Boiling point | 618.3±65.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:100.0(Max Conc. mg/mL);251.55(Max Conc. mM) | | form | A solid | | pka | 14.62±0.20(Predicted) | | color | White to off-white |
| | CYC-065 Usage And Synthesis |
| Uses | Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases[1] with IC50s of 5 and 26 nM, respectively[2]. | | in vivo | To evaluate the therapeutic potential of Fadraciclib as a single agent, USC-ARK-2-derived xenografts are treated daily with Fadraciclib (22.5 mg/kg) for a 3-week period. Tumor size and mouse weight are recorded two times a week. The daily administration of Fadraciclib results in a significant reduction of tumor growth compared with the vehicle-treated mice (P=0.012 starting at day 9 of the treatment). No significant weight loss is reported during the entire treatment period[1]. | | IC 50 | CDK2; CDK9 | | References | [1] Cocco E, et al. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016 Jul 26;115(3):303-11. DOI:10.1038/bjc.2016.198
[2] Sumana Devata, et al. Molecular markers and venous thromboembolism (VTE) in acute myelogenous leukemia (AML) |
| | CYC-065 Preparation Products And Raw materials |
|